Catalog No.
Product Name
Application
Product Information
Citations
-
PARP1 Inhibitor
PARP1-IN-9 is a potent inhibitor of PARP1, exhibiting an IC50 value of 30.51 nM. This compound effectively induces apoptosis in cancer cells, demonstrating significant anticancer activity. PARP1-IN-9 is useful for research applications related to cancer treatment and the study of DNA repair mechanisms. -
PARP1 Inhibitor
PARP1-IN-42 is a potent inhibitor of PARP1, exhibiting an IC50 value of less than 10 nM. This compound has demonstrated significant biological activity in disrupting DNA repair mechanisms, making it a valuable tool in cancer research. Its application can provide insights into the efficacy of PARP1 inhibition in various cancer models. -
PARP1 Degrader
iRucaparib-TP3 is a selective degrader of PARP1, exhibiting a DC50 of 36 nM. This compound is instrumental in research focused on oncology, particularly in the context of BRCA-mutated cancers, as well as in the investigation of neurodegenerative diseases. Its ability to modulate PARP1 levels positions it as a valuable tool for understanding the mechanisms underlying these diseases. -
PARP Inhibitor
ARTD10/PARP10-IN-1 is a potent and non-selective inhibitor of Poly(ADP-ribose) polymerases (PARPs), including ARTD7/PARP15, ARTD8/PARP14, ARTD10/PARP10, and ARTD1/PARP1, exhibiting IC50 values of 1.7 μM, 1.6 μM, 0.8 μM, and 4.4 μM respectively. This compound serves as a valuable tool for investigating the roles of mono-ADP-ribosylation and poly(ADP-ribosylation) in cellular processes. Its ability to inhibit multiple PARP family members makes it suitable for various research applications, including studies on DNA damage repair, cell proliferation, and apoptosis. -
PARP Inhibitor
GPI 15427 is a selective inhibitor of poly (ADP-ribose) polymerase-1 (PARP-1), an enzyme implicated in inflammatory responses. This compound exhibits significant anti-inflammatory activity, particularly in rodent models of gut injury such as splanchnic artery occlusion shock and dinitrobenzene sulfonic acid-induced colitis. GPI 15427 effectively reduces inflammatory cell infiltration, mitigates histological damage, and prevents poly (ADP-ribose) accumulation in the ileum and colon. Its application in research is valuable for studying the role of PARP-1 in inflammatory diseases and potential therapeutic strategies. -
PARP-1 Inhibitor
PARP-1-IN-13 is a potent inhibitor of the enzyme PARP-1, exhibiting an IC50 value of 26 nM. This compound effectively disrupts DNA single-strand break repair mechanisms and exacerbates DNA double-strand breakage. Through the activation of the mitochondrial apoptosis pathway, PARP-1-IN-13 promotes apoptosis in cancer cells, making it a valuable tool for research in cancer therapy and DNA repair pathways. -
PARP1/2 Inhibitor
YCH3292 is a highly potent and selective inhibitor of PARP1 and PARP2, displaying an IC50 of less than 0.001 nM. This compound enhances the stability of PARP-DNA complexes and demonstrates significant antiproliferative effects by inducing double-strand breaks in DNA and increasing the expression levels of γH2AX, P-RPA32, and P-Chk1. YCH3292 effectively causes cell cycle arrest in the S and G2/M phases and promotes apoptosis in tumor cells, making it a valuable reagent for cancer research, particularly in exploring therapeutic strategies targeting PARP pathways. In vivo studies indicate that YCH3292 inhibits tumor growth in the MC38 xenograft mouse model. -
PARP-1 Inhibitor
PARP-1-IN-1 is a highly selective and orally active inhibitor of PARP-1, exhibiting an IC50 of 0.96 nM. This compound demonstrates excellent tolerability and significant single-dose efficacy in the MDA-MB-436 xenotransplantation model. PARP-1-IN-1 is valuable for research in cancer biology and therapeutic applications targeting DNA repair mechanisms. -
PARP1 Inhibitor
PARP1-IN-54 is a selective inhibitor of the poly(ADP-ribose) polymerase 1 (PARP1) enzyme, which plays a crucial role in DNA repair mechanisms. This compound exhibits significant antitumor activity, making it a valuable tool in cancer research. Its inhibition of PARP1 can effectively enhance the therapeutic efficacy of DNA-damaging agents, and it is particularly relevant in studies focusing on cancer biology and treatment strategies involving synthetic lethality. -
PARP1 Inhibitor
PARP1-IN-47 is a highly selective inhibitor of the enzyme PARP1, demonstrating an IC50 value of less than 100 nM. By effectively blocking poly(ADP-ribosyl)ation, PARP1-IN-47 disrupts DNA damage repair mechanisms, leading to apoptosis in tumor cells. This compound holds potential for research applications in both solid tumors and hematological malignancies. -
PARP14 Inhibitor
PARP14 inhibitor 1 is a selective inhibitor of the poly(ADP-ribose) polymerase 14 (PARP14), demonstrating an IC50 of 5.52 nM. This compound exhibits anti-inflammatory properties and a half-life of 182 minutes in mouse liver microsomes. Its efficacy makes it a valuable tool for research in atopic dermatitis and related inflammatory disorders. -
PARP Probe
NCT-TFP is a PARP probe designed for the identification of Poly(ADP-ribose) polymerases (PARP) inhibitors, facilitating research in cancer therapeutics and DNA repair mechanisms. This reagent enables the assessment of PARP activity and its modulation, which is critical for studying cellular responses to DNA damage. NCT-TFP is essential for investigating the role of PARP in various biological processes and for developing targeted therapies. -
PARP-1/2 Inhibitor
PARP-1/2-IN-5 is a potent inhibitor of PARP-1 and PARP-2, with IC50 values of 118 nM and 11 nM, respectively. This compound is ideal for investigating its role in inflammatory diseases and neurodegenerative disorders, providing valuable insights into the therapeutic potential of PARP inhibition in these conditions. Researchers can utilize PARP-1/2-IN-5 to explore the molecular mechanisms underlying these diseases and assess potential treatment strategies. -
PARP-1/2 Inhibitor
HYDAMTIQ is a potent inhibitor of PARP-1 and PARP-2, exhibiting an IC50 range of 29-38 nM. It demonstrates significant anticancer activity, targeting various malignancies such as ovarian, breast, prostate, pancreatic cancers, and glioblastoma multiforme. Additionally, HYDAMTIQ shows anti-inflammatory properties by reducing pulmonary PARP activity and can alleviate symptoms associated with allergen-induced cough and dyspnea. It also exhibits protective effects in in vivo models of cerebral ischemia, asthma, and cancer. -
PARP1/2 Inhibitor
(rac)-Talazoparib is a potent inhibitor of PARP1 and PARP2, with Ki values of 1.2 nM and 0.87 nM, respectively. This orally active compound effectively inhibits cellular PARylation, demonstrating an EC50 of 2.51 nM. It induces DNA damage accumulation and significantly suppresses the proliferation of BRCA1/2-mutated cell lines, including MX-1 and Capan-1, with IC50 values of 0.3 nM and 5 nM, respectively. Additionally, (rac)-Talazoparib shows antitumor efficacy in various mouse models, making it a valuable tool for cancer research. -
PARP1 Inhibitor
PARP1-IN-8 is a potent inhibitor of the PARP1 enzyme, exhibiting an IC50 of 97 nM. This compound demonstrates significant anti-proliferative effects on the human lung adenocarcinoma cell line A549. It is suitable for research applications focused on cancer biology and the therapeutic potential of PARP1 modulation in oncology. -
PARP Inhibitor
Itareparib is a PARP inhibitor that demonstrates significant antineoplastic activity by preventing the repair of DNA damage in cancer cells. This mechanism enhances cell death in tumor tissues, making it a valuable reagent for cancer research, particularly in studies involving homologous recombination repair deficiencies. Its application extends to exploring combination therapies and resistance mechanisms in oncology. -
PARP11 Inhibitor
PARP11 inhibitor ITK7 is a potent and selective inhibitor targeting PARP11. It demonstrates strong inhibitory activity with an IC50 of 14 nM, making it a valuable tool for investigating the biological roles of PARP11. This compound can be utilized in research exploring cellular localization and the functional implications of PARP11 in various cellular contexts. -
PARP Inhibitor
FeTMPyP is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor that exerts protective effects against cell death and mitochondrial dysfunction. It significantly mitigates nitrotyrosine formation and depolarization of the mitochondrial transmembrane potential. FeTMPyP has been shown to alleviate homocysteine-induced nitrosative stress, improve functional and behavioral outcomes in neuropathic pain models, and reduce acute cerebral infarction in ischemic conditions. This compound is valuable for research related to renal aging, ischemic penumbra, and hyperglycemic strokes. -
PARP14 Inhibitor
RBN-3143 is a potent NAD+-competitive inhibitor of PARP14, exhibiting an IC50 of 4 nM. This compound effectively inhibits PARP14-mediated ADP-ribosylation and stabilizes the enzyme in cellular contexts. RBN-3143 is ideal for investigating the role of PARP14 in lung inflammation and other related research applications. -
PARP16 Inhibitor
DB008 is a selective inhibitor of the enzyme PARP16, demonstrating a potent inhibitory effect with an IC50 value of 0.27 μM. This compound features a membrane-permeable acrylamide electrophilic moiety, enabling specific targeting of PARP16. Additionally, DB008 contains an alkyne group that allows for click chemistry applications, specifically facilitating copper-catalyzed azide-alkyne cycloaddition (CuAAc) with azide-containing molecules. Its unique properties make it a valuable tool for biochemical and molecular biology research involving PARP16. -
PARP-1 Inhibitor
DPQ is a selective inhibitor of PARP-1, effectively blocking PARP-1-mediated DNA repair mechanisms and reducing the consumption of NAD+ and ATP. This inhibition leads to a decrease in NF-κB pathway activation, resulting in lowered expression of pro-inflammatory cytokines such as TNF-α and IL-6, along with a reduction in oxidative stress levels. DPQ is applicable in research focused on inflammation-related conditions including acute lung injury, myocardial infarction, and neurodegenerative diseases. -
PARP1/2 Inhibitor
Senaparib is a potent and selective inhibitor of PARP1 and PARP2, functioning through the inhibition of DNA repair pathways. Its mechanism disrupts the ability of cancer cells to repair DNA damage, leading to increased antitumor activity. Senaparib has demonstrated significant efficacy in various preclinical cancer models, making it a valuable tool for research in cancer biology and therapeutic development. -
PARP 1/2 Inhibitor
Venadaparib is a selective and potent inhibitor of PARP1 and PARP2, exhibiting IC50 values of 1.4 nM and 1.0 nM, respectively. This orally active compound effectively impedes the repair of DNA single-strand breaks (SSB). Venadaparib is relevant for research applications targeting solid tumors and investigating the role of PARP in DNA damage response pathways. -
PARP Inhibitor
1,5-Isoquinolinediol is a potent inhibitor of poly(ADP-ribose) polymerase (PARP), exhibiting an IC50 range of 0.18-0.37 μM. This compound is particularly effective in mitigating diabetes-induced oxidative stress through the inhibition of NADPH oxidase in retinal tissues. Its ability to modulate cellular responses to oxidative stress makes it a valuable tool for research into diabetes-related complications and neuroprotection. -
PARP Inhibitor
N-Descyclopropanecarbaldehyde Olaparib is a potent PARP inhibitor, serving as an analogue of Olaparib with a DOTA moiety. This compound is utilized in the synthesis of novel dual EGFR and PARP PROTAC, designated as DP-C-4. Additionally, N-Descyclopropanecarbaldehyde Olaparib can be radiolabeled with F-18 or fluorophores, enabling its application in positron emission tomography (PET) and optical imaging for various tumor types. -
PARP1 Inhibitor
PARPi-FL is a small-molecule fluorescent inhibitor targeting PARP1. It binds selectively to PARP1 and is utilized as a fluorescent imaging agent, facilitating tumor detection, diagnosis, and surgical guidance. This compound serves as a valuable tool in cancer research, offering insights into PARP1 activity in various biological contexts. -
PARP7 Inhibitor
PARP7-IN-15 is a selective inhibitor of PARP7, exhibiting an IC50 of 0.56 nM. This compound demonstrates significant antitumor activity, making it a valuable tool for cancer research. Its potency in inhibiting PARP7 can facilitate studies focused on DNA repair mechanisms and cancer cell proliferation. -
PARP Inhibitor
Nesuparib is a potent inhibitor of PARP 1 and 2, as well as Tankyrase 1 and 2, with IC50 values of 5 nM, 1 nM, and 2 nM, respectively. This orally bioavailable compound demonstrates significant antitumor activity, making it a valuable tool for researching advanced solid tumors. Its selective inhibition of critical DNA repair pathways highlights its potential in cancer therapy and provides important insights into targeted treatment strategies. -
PARP1/2/6 Inhibitor
AZ9482 is a potent inhibitor of PARP1, PARP2, and PARP6, exhibiting IC50 values of 1 nM for both PARP1 and PARP2, and 640 nM for PARP6. This compound effectively disrupts the DNA repair pathway in cancer cells, making it a valuable tool for studying cellular response to DNA damage. AZ9482 is appropriate for applications in cancer research, particularly in the context of synthetic lethality and therapeutic resistance. -
PARP-1/2/7 Inhibitor
PARP7-IN-16 is a selective and orally bioavailable inhibitor of PARP-1, PARP-2, and PARP-7, exhibiting IC50 values of 0.94 nM, 0.87 nM, and 0.21 nM, respectively. This compound serves as a valuable research tool for investigating the roles of PARP enzymes in cellular processes and their implications in oncogenesis. It is particularly relevant for studies focusing on breast cancer and prostate cancer, providing insights into therapeutic strategies that target DNA repair mechanisms. -
PROTAC PARP1 Degrader
PROTAC PARP1 degrader-1 is a potent degrader targeting PARP1 through the PROTAC mechanism. This compound facilitates the activation of the cGAS/STING immune pathway, enhancing T cell-mediated cytotoxicity against tumor cells. Additionally, by inhibiting DNA damage repair, PROTAC PARP1 degrader-1 promotes the accumulation of cytosolic DNA fragments, making it a valuable tool for research in cancer immunotherapy and the study of DNA repair mechanisms. -
PARP Inhibitor
K-756 is a selective tankyrase (TNKS) inhibitor that effectively inhibits the ADP-ribosylation activity of TNKS1 and TNKS2, exhibiting IC50 values of 31 nM and 36 nM, respectively. This compound plays a significant role in the study of various cancer-related pathways and cellular processes influenced by tankyrase activity. K-756 is applicable in research focused on DNA repair mechanisms, cellular signaling, and the modulation of Wnt signaling pathways. -
PARP10/15 Inhibitor
PARP10/15-IN-1 is a selective inhibitor targeting both PARP10 and PARP15, exhibiting IC50 values of 160 nM and 370 nM, respectively. This compound serves as a valuable tool for cancer research, enabling the investigation of PARP10 and PARP15's roles in tumorigenesis and therapeutic resistance. Its dual inhibitory properties facilitate studies aimed at understanding the molecular mechanisms of cancer progression and the potential for targeted therapies. -
PARP10 Inhibitor
PARP10-IN-3 is a selective inhibitor of the mono-ADP-ribosyltransferase PARP10, exhibiting an IC50 of 480 nM against human PARP10. Additionally, it demonstrates significant inhibitory activity towards PARP2 and PARP15 with IC50 values of 1.7 μM. This compound serves as a valuable tool in research applications targeting the role of PARP enzymes in cellular processes and their implications in various diseases, including cancer. -
PARP1/2 Inhibitor
Simmiparib is a potent and orally active inhibitor of PARP1 and PARP2, demonstrating IC50 values of 1.75 nM and 0.22 nM, respectively. This compound effectively induces the accumulation of DNA double-strand breaks and triggers G2/M phase arrest in homologous recombination repair-deficient cells, leading to apoptosis. Simmiparib exhibits significant antitumor activity in various cancer models, including xenografts in nude mice, making it a valuable tool for cancer research and therapeutic development. -
PARP-1 Inhibitor
PARP1-IN-5 dihydrochloride is a potent and selective inhibitor of PARP-1, with an IC50 of 14.7 nM. This compound exhibits low toxicity and is suitable for oral administration. PARP1-IN-5 dihydrochloride is primarily utilized in cancer research to investigate the role of PARP-1 in tumorigenesis and therapy resistance. -
PARP7 Inhibitor
PARP7-IN-17 is a potent PARP7 inhibitor with an IC50 of 4.5 nM, demonstrating effective oral bioavailability. This compound exhibits significant antitumor activity, making it a valuable tool for research into cancer therapeutics and the biological role of PARP7 in tumorigenesis. Its selective inhibition of PARP7 may aid in the development of targeted cancer treatments. -
PARP7 Inhibitor
PARP7-IN-22 is a potent PARP7 inhibitor with an IC50 of 0.6 nM. This compound is orally active and enhances type I interferon signaling in vitro, facilitating T cell infiltration into tumor tissues and significantly inhibiting tumor growth. PARP7-IN-22 is of particular interest for research in cancer immunotherapy, providing valuable insights into therapeutic strategies that target immune responses in oncology. -
PARP Inhibitor
PARP7-IN-16 free base is a selective, orally active inhibitor of PARP-1, PARP-2, and PARP-7, exhibiting IC50 values of 0.94 nM, 0.87 nM, and 0.21 nM, respectively. This compound is valuable for investigating the role of PARP enzymes in DNA repair mechanisms and is particularly relevant in studies focused on breast and prostate cancer. Researchers can utilize PARP7-IN-16 free base to explore therapeutic strategies targeting these types of malignancies. -
PARP1 Inhibitor
PARP1-IN-11 is a selective inhibitor of the poly(ADP-ribose) polymerase 1 (PARP1) enzyme, demonstrating a potent inhibitory activity with an IC50 value of 0.082 µM. This compound exhibits complete inhibition of PARP2 and significantly inhibits the activity of PARP3, as well as tankyrases TNKS1 and TNKS2. PARP1-IN-11 is valuable for research applications focused on DNA repair mechanisms, cancer therapeutics, and the study of cellular responses to genotoxic stress. -
PARP14 PROTAC Degrader
RBN012811 is a selective PROTAC degrader that targets PARP14, facilitating its degradation through a ternary complex with cereblon by binding at the NAD+ site. With an IC50 of 10 nM, RBN012811 efficiently reduces endogenous PARP14 levels in various cell lines and primary human macrophages. This reduction is associated with decreased IL-10 production and IFN-β mRNA, alongside an increase in phosphorylated STAT1, thereby enhancing inflammatory signaling and inhibiting interferon-induced ADPr condensate formation. RBN012811 also influences viral replication dynamics, promoting HSV1 replication while diminishing VSV replication, making it valuable for research in cancer biology and viral infections. -
PARP1 Inhibitor
PARP1-IN-33 is a potent inhibitor of PARP1, exhibiting an IC50 of 0.41 nM. This compound demonstrates significant cytoprotective effects on retinal cells, with an EC50 of 0.02 nM in inhibiting MTS activity in H2O2-induced human retinal pigment epithelial cells. PARP1-IN-33 is valuable for research applications aimed at understanding retinal oxidative stress and developing therapeutic strategies for retinal diseases. -
PARP-1 Inhibitor
A-620223 is a potent inhibitor of PARP-1, exhibiting a Ki of 8 nM and an EC50 of 3 nM in whole cell assays. This compound demonstrates significant in vivo efficacy in murine models, particularly in the B16F10 melanoma model when used in combination with Temozolomide and in the MX-1 breast xenograft model with Cisplatin. A-620223 is suitable for research applications focusing on melanoma and breast cancer therapy. -
PARP Inhibitor
Saruparib is a potent and selective PARP inhibitor, primarily targeting PARP1 with an IC50 value of 3 nM and PARP2 with an IC50 of 1400 nM. This orally active compound demonstrates significant anti-proliferative effects and is particularly effective in inhibiting the growth of cells exhibiting deficiencies in DNA repair mechanisms. Saruparib is commonly utilized in research focused on cancer treatment strategies, particularly in the context of homologous recombination repair-deficient tumors. -
PARP1 Inhibitor
Fluzoparib is a highly potent oral inhibitor of PARP1, demonstrating an IC50 of 1.46 ± 0.72 nM in cell-free enzymatic assays. This compound selectively targets homologous recombination repair (HR)-deficient cells while sensitizing both HR-deficient and HR-proficient cells to cytotoxic agents. With favorable pharmacokinetic properties in vivo, Fluzoparib is an important reagent for studying BRCA1/2-mutant relapsed ovarian cancer and related therapeutic strategies. -
PARP14 Inhibitor
RBN012759 is a potent and selective inhibitor of PARP14, exhibiting an IC50 of less than 3 nM. It demonstrates 300-fold selectivity for monoPARPs and 1000-fold selectivity for polyPARPs. RBN012759 has been shown to diminish pro-tumor macrophage activity and trigger inflammatory responses in tumor explants, making it a valuable tool for research in cancer biology and immune modulation. -
PARP Inhibitor
Basroparib is a selective inhibitor of tankyrase (TNKS1/TNKS2) with IC50 values of 29.94 nM and 3.68 nM, respectively, and exhibits limited activity against PARP1 (IC50 > 10 μM). This compound stabilizes AXIN1/2 proteins and effectively disrupts the Wnt/β-catenin signaling pathway, leading to inhibition of tumor cell proliferation and induction of apoptosis. Basroparib is particularly relevant for research in colorectal cancer (CRC) models bearing KRAS mutations, such as G12V/G12D, and demonstrates potential to overcome resistance to MEK inhibitors, providing synergistic antitumor effects. -
PARP Inhibitor
Benzamide is a potent inhibitor of poly(ADP-ribose) polymerase (PARP), demonstrating significant neuroprotective effects. It has been shown to protect against neurotoxicity induced by glutamate and methamphetamine in vitro. In vivo studies indicate that Benzamide can mitigate methamphetamine-induced dopamine depletions in mice without acute effects on striatal dopamine metabolism or body temperature regulation. Its dual role in neuroprotection and PARP inhibition makes it a valuable tool in neuropharmacology research. -
PARP10 Inhibitor
OUL232 is a potent inhibitor of poly(ADP-ribose) polymerase 10 (PARP10) and other mono-ADP-ribosyl transferases including PARP7, PARP11, PARP12, PARP14, and PARP15. With an IC50 of 7.8 nM, OUL232 represents the most effective PARP10 inhibitor characterized to date and is the first reported inhibitor targeting PARP12. This compound is valuable for studying the biological roles of PARP10 and PARP12 in cellular processes and may facilitate research into therapeutic strategies involving these targets.
